143 related articles for article (PubMed ID: 18773859)
1. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma.
Uhm KO; Lee ES; Lee YM; Kim HS; Park YN; Park SH
Oncol Res; 2008; 17(4):151-7. PubMed ID: 18773859
[TBL] [Abstract][Full Text] [Related]
2. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
[TBL] [Abstract][Full Text] [Related]
3. Aberrant DNA methylation of integrin alpha4: a potential novel role for metastasis of cholangiocarcinoma.
Uhm KO; Lee JO; Lee YM; Lee ES; Kim HS; Park SH
J Cancer Res Clin Oncol; 2010 Feb; 136(2):187-94. PubMed ID: 19655168
[TBL] [Abstract][Full Text] [Related]
4. Role of epigenetic alterations in cholangiocarcinoma.
Tischoff I; Wittekind C; Tannapfel A
J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma.
Liu XF; Kong FM; Xu Z; Yu SP; Sun FB; Zhang CS; Huang QX; Zhou XT; Song ZW
Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):407-11. PubMed ID: 17690039
[TBL] [Abstract][Full Text] [Related]
6. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.
Isomoto H; Mott JL; Kobayashi S; Werneburg NW; Bronk SF; Haan S; Gores GJ
Gastroenterology; 2007 Jan; 132(1):384-96. PubMed ID: 17241887
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.
Yang B; House MG; Guo M; Herman JG; Clark DP
Mod Pathol; 2005 Mar; 18(3):412-20. PubMed ID: 15467712
[TBL] [Abstract][Full Text] [Related]
8. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
[TBL] [Abstract][Full Text] [Related]
10. Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors.
Sriraksa R; Zeller C; Dai W; Siddiq A; Walley AJ; Limpaiboon T; Brown R
Cancer Prev Res (Phila); 2013 Dec; 6(12):1348-55. PubMed ID: 24089088
[TBL] [Abstract][Full Text] [Related]
11. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma.
Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S
Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562
[TBL] [Abstract][Full Text] [Related]
12. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.
Kim BH; Cho NY; Choi M; Lee S; Jang JJ; Kang GH
Arch Pathol Lab Med; 2007 Jun; 131(6):923-30. PubMed ID: 17550320
[TBL] [Abstract][Full Text] [Related]
13. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma.
Lee S; Kim WH; Jung HY; Yang MH; Kang GH
Am J Pathol; 2002 Sep; 161(3):1015-22. PubMed ID: 12213730
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.
Wehbe H; Henson R; Meng F; Mize-Berge J; Patel T
Cancer Res; 2006 Nov; 66(21):10517-24. PubMed ID: 17079474
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma.
Chen YJ; Tang QB; Zou SQ
World J Gastroenterol; 2005 Mar; 11(9):1333-8. PubMed ID: 15761971
[TBL] [Abstract][Full Text] [Related]
16. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma.
Andresen K; Boberg KM; Vedeld HM; Honne H; Hektoen M; Wadsworth CA; Clausen OP; Karlsen TH; Foss A; Mathisen O; Schrumpf E; Lothe RA; Lind GE
Epigenetics; 2012 Nov; 7(11):1249-57. PubMed ID: 22983262
[TBL] [Abstract][Full Text] [Related]
17. CpG-island methylation study of liver fluke-related cholangiocarcinoma.
Sriraksa R; Zeller C; El-Bahrawy MA; Dai W; Daduang J; Jearanaikoon P; Chau-In S; Brown R; Limpaiboon T
Br J Cancer; 2011 Apr; 104(8):1313-8. PubMed ID: 21448164
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Guo N; Chen R; Li Z; Liu Y; Cheng D; Zhou Q; Zhou J; Lin Q
Acta Biochim Biophys Sin (Shanghai); 2011 May; 43(5):354-61. PubMed ID: 21450690
[TBL] [Abstract][Full Text] [Related]
20. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma.
Chen YJ; Luo J; Yang GY; Yang K; Wen SQ; Zou SQ
World J Gastroenterol; 2012 Aug; 18(29):3849-61. PubMed ID: 22876037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
